OLB Group Gets a Second Nasdaq Cure Period to January 2027 — While the Exchange's $5 Million Floor Sits Stayed at the SEC
The OLB Group said Friday that Nasdaq has given it another 180 calendar days to get its share price back above a dollar. In an August 14 announcement, the New York fintech said it received a letter that day from the Listing Qualifications Department of The Nasdaq Stock Market LLC granting an additional compliance period that runs to January 25, 2027. The stock closed Friday at $0.298, down 4.58% on the day, according to StockScan; StockAnalysis put the company's market capitalization at about $4.37 million on roughly 14.65 million shares outstanding, which is consistent with that close.
The company's release was careful about what the letter does and does not do. It said the Nasdaq letter has no immediate effect on the listing or trading of the Company's common stock, which continues to trade on the Nasdaq Capital Market under the symbol OLB. The company said it intends to monitor the closing bid price of its common stock and to consider all available options to regain compliance, including implementing a reverse stock split. Any reverse split, the release added, would have to be completed no later than ten business days prior to January 25, 2027 in order to timely regain compliance. It closed with the standard caution: there can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or otherwise maintain its listing on the Nasdaq Capital Market.
The release also carried a warning the company was not required to volunteer, and it is the sharpest sentence in the document. If compliance is not demonstrated by January 25, 2027, OLB said, Nasdaq staff will provide written notification that the securities will be delisted, at which point the company may request a hearing before a Nasdaq Hearings Panel — but a timely request for a hearing following a second 180-day compliance period would not stay the suspension of the company's securities from trading. In other words, the appeal after this deadline is an appeal from off the exchange, not from on it.
This is the second half of a clock that started in January. In a Form 8-K filed February 3, OLB disclosed that Nasdaq notified it on January 29, 2026 that it no longer met the $1.00 minimum bid price requirement of Listing Rule 5550(a)(2), and that under Listing Rule 5810(c)(3)(A) it had 180 calendar days, to July 28, 2026, to cure. That filing set out the test that still applies: compliance is regained when the closing bid price is $1.00 or more for a minimum of ten consecutive business days. Counting from July 29, the second period's January 25, 2027 end date is exactly 180 days out.
The second 180-day period is not automatic. Under the compliance-period rule as recited in issuers' own filings — Datavault AI's February 27 Form 8-K and Beyond Meat's March 2026 Form 8-K describe it in the same terms — a company qualifies for the extension only if it satisfies the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market except the bid price requirement, and gives written notice of its intention to cure the deficiency, including by effecting a reverse split if necessary. Note that the second test is the initial listing standards, which are generally more demanding than the continued listing standards a company has been measured against. OLB's Friday release did not say which of those standards it demonstrated, and Nasdaq does not publish that analysis; we found no OLB filing or release disclosing it. Readers should treat the grant itself as the only public evidence on that point.
The financial backdrop is thin. StockAnalysis lists trailing twelve-month revenue of $8.01 million, down 31.3%, against net income of negative $6.64 million, with a 52-week range of $0.2746 to $1.8000. The company's most recent quarterly report on file at the time of writing covers the March 2026 quarter and was filed May 15, the same day as a Form 12b-25 late-filing notice.
Dilution is the other half of the arithmetic, and it cuts against the share count the market value rests on. A resale registration statement OLB filed on April 16, 2026 states that 12,505,749 shares were issued and outstanding as of March 31, 2026 — against roughly 14.65 million now, an increase of about 17% in under five months. That same filing registered 6,428,570 shares for resale by Armistice Capital Master Fund: 2,857,142 underlying pre-funded warrants exercisable at $0.0001 and 3,571,428 underlying common warrants exercisable at $0.92. The pre-funded warrants are shares in all but name; the $0.92 warrants sit far above Friday's close, but a reverse split would adjust that strike along with everything else. On August 12 the company filed an 8-K disclosing a sales agreement dated August 7 for an at-the-market offering of up to $1.6 million of common stock through Maxim Group at a 3% commission — a program roughly a third the size of the company's entire market value, which OLB is under no obligation to draw on.
The number that makes Friday's letter interesting is not the deadline. It is the market value. On July 22, 2026, the SEC's Division of Trading and Markets, acting under delegated authority, approved a Nasdaq rule change, File No. SR-NASDAQ-2026-004 (Release No. 34-105971), adopting a new continued listing requirement that companies maintain a Market Value of Listed Securities of at least $5 million. The approval order states that a company whose MVLS stays below that level for a period of 30 consecutive business days would not be entitled to any cure or compliance period; a Staff Delisting Determination would inform the company that its securities are immediately subject to suspension and delisting.
MVLS is a specific calculation, not a loose synonym for size. The approval order itself does not spell it out, cross-referencing instead Nasdaq Rule 5005(a)(23), which defines Market Value as the consolidated closing bid price multiplied by the measure to be valued, and Rule 5005(a)(22), which defines Listed Securities. Securities-law analyses of the rule describe the measure as the total outstanding shares of the listed class, excluding authorized but unissued shares, treasury shares, unexercised options and warrants, unconverted convertible securities and shares reserved under equity plans. It also differs from the market value of unrestricted publicly held shares, because shares held by officers, directors and large holders count toward MVLS even where they are stripped out of that float measure. A last-sale-based market capitalization figure of the sort quoted above is a proxy for MVLS, not the exchange's own computation.
The appeal path under the approved rule is unusually narrow. Amendments to Rule 5815(a)(1)(B) mean a timely hearing request does not stay the trading suspension, so the security moves to the over-the-counter market while the appeal is pending. A Hearings Panel may still find that Nasdaq erred, or grant an exception of up to 180 days from the Staff Delisting Determination — but during that exception the company must demonstrate that it meets all requirements for initial listing, which are generally more stringent than the continued listing requirements it had been failing.
None of that is in force. On July 29, 2026, Cemtrex and the Small Public Company Coalition filed notices of intention to petition the Commission for review of the delegated approval; Thomson Reuters has reported that the SEC received several such notices. Under Rule 431(e) of the SEC's Rules of Practice, filing a notice of intent to petition for review automatically stays an action taken under delegated authority, subject to narrow exceptions; no separate Commission vote is required. The SEC's Deputy Secretary wrote to Nasdaq on July 29 stating that the July 22 order is stayed until the Commission orders otherwise. Law firm analyses published in late July and early August by Mayer Brown, Paul Weiss and others describe the same sequence, and nothing we reviewed through Friday's close indicates the stay has been lifted or that the Commission has yet ruled on review.
One of the two named petitioners illustrates the stakes. Cemtrex is itself a Nasdaq-listed micro cap: StockAnalysis put its market capitalization at roughly $3.34 million at the August 13 close of $3.02, on about 1.11 million shares, against trailing twelve-month revenue of $69.69 million and net income of negative $27.72 million. Its 52-week range of $2.38 to $220.50 is an artifact of serial reverse splits — split records show a 1-for-60 in October 2024, a 1-for-15 in September 2025 and a 1-for-10 in June 2026. That history matters beyond the chart: a cumulative ratio of that size over the prior two years would, under the reverse-split rule discussed below, leave Cemtrex ineligible for any bid price compliance period should it fail that standard. A company can carry substantial revenue and still sit well under a $5 million market value threshold.
Netcapital, another Nasdaq micro cap, told shareholders on July 31 that the stay had removed an immediate threat. Chief Executive Todd Violette said: Most importantly, this development gives our shareholders clarity: the MVLS rule is not in effect today, and while it remains stayed, the Company's work continues. The same release characterized the stay as procedural rather than a determination on the merits of the rule, and noted that the company remains subject to every other applicable Nasdaq continued listing requirement.
That caveat is the operative one. The stay suspends a new standard; it removes nothing that already exists. Bid price, stockholders' equity, market value of publicly held shares and the existing MVLS standards of $35 million on the Capital Market and $50 million on the Global Market all continue to apply on their own terms — as alternative compliance standards rather than absolute floors — and Nasdaq staff continue to issue deficiency notices under them, as OLB's own January letter shows.
There is also a hard floor already operating beneath the bid price rule. An amendment to Rule 5810(c)(3)(A)(iii), approved by the SEC on December 5, 2025, published in the Federal Register on December 10 and operative 45 days after approval, provides that a bid price failure is determined to exist where a security has a closing bid price of $0.10 or less for ten consecutive business days, regardless of whether the company is under any compliance period, and directs the Listing Qualifications Department to issue a Staff Delisting Determination. OLB's Friday close of $0.298 sits above that line, but the margin is measured in cents.
A second constraint bears on the reverse split OLB says it is weighing, and it is in force. Rule 5810(c)(3)(A)(iv), approved by the SEC in January 2025 (Release No. 34-102245), reads: if a Company's security fails to meet the continued listing requirement for minimum bid price and the Company has effected a reverse stock split over the prior one-year period; or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, then the Company shall not be eligible for any compliance period. The bar is conditional and prospective, not a present state: it bites only if and when a new bid price failure occurs while a split sits inside those look-back windows. A split executed to cure the current deficiency would therefore foreclose a future compliance period for a year if the price fell back through a dollar.
What to watch from here is procedural, not directional. First, whether the Commission grants review of SR-NASDAQ-2026-004 and, if so, whether it affirms, modifies, sets aside or remands the approval; Rule 431 sets no deadline for that decision, and the question could ultimately reach a federal court. Second, whether OLB effects a reverse split and, if it does, on what ratio and against what share count — a count that the April registration statement and the August at-the-market program can both move. Nothing in this article is a view on OLB's or Cemtrex's shares. What the filings establish is narrower and worth stating plainly: OLB has a dated deadline, a declining revenue base, an expanding share count with registered warrant overhang, a market value near the level of a threshold that is currently stayed rather than repealed, an appeal route after January 2027 that would not keep the stock on the exchange, and an explicit company statement that compliance is not assured.
